Radiation Oncology, Azienda Ospedaliero - Universitaria Careggi, University of Florence, Florence, Italy.
Radiation Oncology, Azienda Ospedaliero - Universitaria Careggi, University of Florence, Florence, Italy.
Oral Oncol. 2017 Nov;74:142-147. doi: 10.1016/j.oraloncology.2017.10.004. Epub 2017 Oct 16.
The aim of our work was to report on the clinical outcome of a moderately hyprofractionated radiotherapy regimen in elderly patients affected by head and neck squamous cell carcinoma (HNSCC).
HNSCC aged ≥65 deemed unsuitable for curatively-intended concurrent chemo-radiotherapy or high-dose radiotherapy by clinical judgement were further evaluated with the Geriatric 8 (G8) questionnaire and Charlson comorbidity index (CCI). In case of a G8 score ≤14, a de-intensified radiation schedule of 40 Gy delivered in 16 fractions was prescribed.
Thirty-six patients were treated between 2011 and 2016. The median age of the cohort was 77.5 (range: 65-91 years) with a combined ECOG PS of 2-3 in 77.8% and CCI of ≥8 in 25% patients, respectively. At a median follow-up of 13 months (range 2-62 months), the 6-month and 1-year rates of loco-regional control and progression-free survival were 42%, 28% and 36% and 20%, respectively. At univariate analysis, log-rank test showed that age >75 years (p=0.036), worse PS (ECOG≥2; p=0.027), lower G8 score (<9; p=0.027) and PTV volume greater than 200 cc (p=0.038) had a significant correlation with PFS. The negative impact of the PTV volume on PFS was the only parameter confirmed in the multivariate analysis (HR 2.68; 95% CI: 1.24-5.81, p=0.013). No grade 4-5 toxicity was observed, while 13/36 patients (36%) had G3 acute side effects.
The hypofractionated radiation schedule evaluated provides clinical benefit with low toxicity in frail, elderly patients affected by locally advanced HNSCC.
我们的工作旨在报告一种中度超分割放疗方案在老年头颈部鳞状细胞癌(HNSCC)患者中的临床结果。
临床判断认为不适合接受根治性同期放化疗或高剂量放疗的 HNSCC 老年患者(年龄≥65 岁),进一步用老年 8 项问卷(G8)和 Charlson 合并症指数(CCI)进行评估。如果 G8 评分≤14,则采用 40 Gy 分 16 次的减量化放疗方案。
2011 年至 2016 年期间,36 例患者接受了治疗。该队列的中位年龄为 77.5 岁(范围:65-91 岁),ECOG PS 综合评分为 2-3 的患者占 77.8%,CCI≥8 的患者占 25%。中位随访时间为 13 个月(范围 2-62 个月),6 个月和 1 年的局部区域控制率和无进展生存率分别为 42%、28%和 36%和 20%。单因素分析显示,年龄>75 岁(p=0.036)、PS 较差(ECOG≥2;p=0.027)、G8 评分较低(<9;p=0.027)和 PTV 体积大于 200cc(p=0.038)与 PFS 显著相关。多因素分析证实,PTV 体积对 PFS 的负面影响是唯一的参数(HR 2.68;95%CI:1.24-5.81,p=0.013)。未观察到 4-5 级毒性,36 例患者中有 13 例(36%)出现 3 级急性不良反应。
评估的超分割放疗方案在局部晚期 HNSCC 体弱老年患者中提供了临床获益,且毒性较低。